# Dose-Finding of Propranolol in Combination With Metronomic Fixed Oral Cyclophosphamide Based on Bivariate Efficacy-tolerability Outcome in Patients With Locally Advanced or Metastatic Angiosarcoma: A Collaborative and Innovative Phase I-II Sequential Trial by the French Sarcoma Group (GSF/GETO)

> **NCT02732678** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Assistance Publique Hopitaux De Marseille** · enrollment: 24 (estimated)

## Conditions studied

- Angiosarcoma

## Interventions

- **DRUG:** PROPRANOLOL

## Key facts

- **NCT ID:** NCT02732678
- **Lead sponsor:** Assistance Publique Hopitaux De Marseille
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-05
- **Primary completion:** 2018-05
- **Final completion:** 2019-05
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2016-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02732678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02732678, "Dose-Finding of Propranolol in Combination With Metronomic Fixed Oral Cyclophosphamide Based on Bivariate Efficacy-tolerability Outcome in Patients With Locally Advanced or Metastatic Angiosarcoma: A Collaborative and Innovative Phase I-II Sequential Trial by the French Sarcoma Group (GSF/GETO)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02732678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*